FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first - Pharmaceutical Technology

Priovant is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies. The biotech is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies immediately. Priovant is also evaluating LCredit: luchschenF / Shutterstock.com. Priovant Therapeutics has secured approval from the US Food and Drug Administration (FDA) for its oral therapy Lisraya (brepocitinib) in a rare autoimmune disease called dermatomyositis, becoming the first targeted therapy authorised for this condition. Based on the FDA’s verdict, the once-daily, dual tyrosine kinase 2 (TYK) and Janus kinase…

Source: Pharmaceutical Technology